>>> US Gapping up

Gapping up 

Select Index ETFs trading higher:

  • IWM +1.6%, SPY +1.1%, DIA +1.1%, QQQ +0.8%

Other news:

  • TBIO +63.9% (expands collaboration to develop mRNA vaccines with Sanofi)
  • APYX +28.7% (received clearance to sell Helium Plasma Technology products in five new countries)
  • INO +14.3% (receives $71 million funding from the U.S. Department of Defense to support the large-scale manufacture of the company's proprietary CELLECTRA 3PSP smart device and the procurement of CELLECTRA 2000 devices)
  • MYOV +8.8% (announces top-line results from SPIRIT 1; receives Priority Review for oral relugolix from FDA)
  • GO +8.7% ( to join S&P MidCap 400)
  • SCVL +7.1% (provided store re-opening update; Q2 comp sales are up +28.1% yr/yr second quarter-to-date)
  • NRZ +6.3% (raised quarterly common stock dividend)
  • KRTX +3.8% (reports positive outcome of End-of-Phase 2 meeting with the FDA for KarXT)
  • TELL +3.5% (names Charif Souki as Executive Chairman)
  • SDGR +3.1% (announced a significant expansion of its work to discover novel antiviral therapeutics for COVID-19; announced a strategic collaboration with Thermo Fisher Scientific to extend the use of cryo-EM)
  • VSTM +2.2% (announced preclinical proof-of-concept for combining VS-6766 with defactinib to treat metastatic uveal melanoma)
  • ZS +1.9% (prices offering of of $1.0 bln of 0.125% convertible senior notes due 2025)
  • EAT +1.6% (to join S&P SmallCap 600)
  • PD +1.4% (prices offering of $250 mln of 1.25% Convertible Senior Notes due 2025)
  • CC +1.3% (EPA has approved Glyclean Hard Surface Cleaner for use against SARS-COV-2)

Analyst comments:

  • MT +5.3% (upgraded to Hold from Sell at Societe Generale)
  • ON +3.6% (upgraded to Overweight from Neutral at Piper Sandler)
  • PAG +2.7% (upgraded to Buy from Hold at The Benchmark Company)
  • NUVA +1.8% (upgraded to Buy from Hold at Needham)
  • FAST +1.6% (upgraded to Neutral from Underweight at JP Morgan)
  • AAPL +1.5% (target raised to $400 from $325 at UBS)
  • ABBV +1.3% (upgraded to Overweight from Neutral at Atlantic Equities)
  • AMBA +1.1% (initiated with a Buy at Rosenblatt)